PMID: 9432047Jan 31, 1998Paper

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

British Journal of Haematology
J E ParkerG J Mufti

Abstract

Nineteen patients with high-risk myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) received fludarabine, cytarabine, granulocyte-colony stimulating factor (G-CSF), and idarubicin chemotherapy (de novo MDS/MDS-AML, nine; relapsed/refractory MDS/AML, seven; therapy-related MDS, three). Median age was 44 years and median disease duration 10 months. 16/19 (84%) patients had abnormal cytogenetics with seven (37%) harbouring abnormalities of chromosome 7. 18/19 (94.7%) patients responded to FLAG-idarubicin with 12 (63%) achieving complete remission (CR) (< 5% blasts and normal cytogenetics). 7/9 (78%) patients with de novo MDS/MDS-AML achieved CR compared to 5/10 (50%) with alternative diagnoses. Response was associated with age < 50 years, disease duration < 3 months, and cytogenetics other than abnormalities of chromosome 7. Haemopoietic regeneration was rapid in most patients and there were no toxic deaths. Nine patients received a second course of chemotherapy, three have proceeded to allogeneic bone marrow transplant and three to autologous blood stem cell/bone marrow transplantation. Follow-up is short (median 10 months). 12/19 (63%) patients remain alive and 5/12 (42%) have relapsed at a median 5 months following CR...Continue Reading

Citations

Nov 26, 1999·Cancer·H D Preisler
Jan 5, 2002·Hematological Oncology·R J Frewin, S A Johnson
Aug 16, 2001·International Journal of Hematology·Jacqueline Boultwood, James S Wainscoat
Oct 21, 2004·Best Practice & Research. Clinical Haematology·Francine M Foss
Dec 15, 1988·Biochemical and Biophysical Research Communications·A SatoM Okada
Dec 12, 2001·Critical Reviews in Oncology/hematology·F D Pisani, A Rainaldi
Dec 10, 1999·Critical Reviews in Oncology/hematology·G LeoneL Pagano
May 26, 1999·The New England Journal of Medicine·M L Heaney, D W Golde
Nov 23, 2006·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·F ScamardellaM Brini
Jan 10, 2012·Leukemia & Lymphoma·Shaun FlemingJohn F Seymour
Apr 12, 2003·Leukemia & Lymphoma·Tadeusz Robak
Dec 6, 2011·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·L Domínguez SenínE Martín Chacón
Apr 3, 2010·Hematology/oncology Clinics of North America·David P Steensma
Oct 7, 2005·Pharmacotherapy·Dawn M NiedermeierPhilip D Hall
Jul 3, 2004·The Lancet Oncology·Felicetto Ferrara
Jul 2, 2015·Current Hematologic Malignancy Reports·Martin WermkeUwe Platzbecker

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.